Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Mount Sinai grants Plexcera license to develop rhAC-based treatments

Sep. 17, 2013

Versartis obtains European orphan drug status for VRS-317

Sep. 16, 2013

Procysbi approved in E.U. for nephropathic cystinosis

Sep. 16, 2013

Piramal Enterprises discloses novel GPR40 agonists

Sep. 16, 2013

Camurus receives option-exercise milestone for CAM-2029

Sep. 16, 2013

AAV8 gene therapy corrects experimental primary hyperoxaluria type 1

Sep. 16, 2013

Sanofi withdraws lixisenatide NDA in the U.S.

Sep. 13, 2013

Italian group discloses novel GSK-3 beta inhibitors

Sep. 13, 2013

Dainippon Sumitomo Pharma reports discovery of glucagon receptor antagonists

Sep. 13, 2013

Amgen presents novel GPR119 agonists at ACS meeting

Sep. 13, 2013

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...